{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031477","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.597690+00:00","generated_at":"2026-05-31T09:42:21.557328+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pulmatrix Q2 2024 net loss widens to $5.8M; cash runway extended to Q4 2026","bullets":["Net loss widened to $5.8M ($1.59/sh) from $3.8M ($1.04) a year ago; revenue fell to $1.6M from $1.8M.","Cash and equivalents $12.4M plus $1.4M restricted cash released; projected cash runway into Q4 2026 after MannKind transactions.","Recorded $2.6M loss on disposal group for assets transferred to MannKind in connection with iSPERSE technology validation.","Halted Phase 2b enrollment for PUR1900 with Cipla; wind down by Q3 2024; no further development funding, 2% royalty on future ex-US sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031477","json":"https://secwatch.observer/filing/0001493152-24-031477.json","markdown":"https://secwatch.observer/filing/0001493152-24-031477.md","text":"https://secwatch.observer/filing/0001493152-24-031477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315224031477/0001493152-24-031477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315224031477/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:42:21.557328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}